Dr. Davey’s interests are in developing small molecule therapies and understanding infection mechanism of emergent viruses such as filoviruses, arenaviruses and henipaviruses. He received his PhD in Microbiology from the University of Adelaide, Australia, in 1993. He then performed postdoctoral work in the laboratory of Dr. James Cunningham at the Harvard Medical School until 2000 where he was the first to determine the crystal structure and biochemically characterize a mammalian retrovirus (MuLV) envelope glycoprotein. He was then recruited as an Assistant Professor at the University of Texas Medical Branch (UTMB) in Texas, USA. While at UTMB, in 2006, he started work with Ebola virus in the newly constructed Shope lab, the first BSL4 laboratory built at a university in the USA. He then moved to Texas Biomedical Research Institute in San Antonio in 2011 where he established a program for drug development against hemorrhagic fever viruses. In 2018 he moved to Boston University to the newly opened National Emerging Infectious Diseases Laboratory (NEIDL) where he continues to work on virus host factor identification and antiviral drug development for BSL4 pathogens. He has made significant contributions in understanding the entry mechanism of filoviruses into host cells and using the virus as a probe to better understand general cell biological processes that include macropinocytosis and autophagy. He has also worked with multiple groups to identify and characterize new small molecule scaffolds with antiviral properties, using these as potential therapies and as probes to better study infection mechanism.